(TT) was carried out on 31 patients with endemic Egyptian hepatosplenomegaly and on 14 healthy controls. The functional activities of factors II, VII, IX and X and protein C were measured. Patients were classified as pure hepatosplenic schistosomiasis (n = 17) and schistosomiasis with concomitant chronic hepatitis B virus infection (n = 14) . Results Those with an alcohol or drug intake which might have interfered with the blood coagulation profile were excluded.
Blood (9 volumes) was collected in sodium citrate solution (0 -11 mol/l) (1 volume) under aseptic conditions by clean venepuncture, without frothing, and with minimal venous stasis. Citrated plasma was prepared, kept at 4°C, and tested within four hours. Special haemostatic tests were carried out according to the manufacturer's instructions (Behring Institute Mannheim, Germany) using the Fibrintimer (Behring Institute). These include measuring the prothrombin time (PT) using Thromborel reagent, the partial thromboplastin time (PI-IT) using Pathromtin reagent, and the thrombin time (TT) using Test Thrombin reagent, as well as assay of the vitamin K-dependent coagulation proteins.
Assays of coagulation factors II, VII, and X were based on comparison of the degree of correction of the long PT of the factor deficient plasma after the subsequent addition of dilutions of the test plasma using Clotting Factor II Deficient Plasma, Clotting Factor VII Deficient Plasma, and Clotting Factor X Deficient Plasma reagents, respectively. Assay of coagulation factor IX was based on a comparison of the degree of correction of the prolonged P7T1 of factor IX deficient plasma after the addition of dilutions of the test plasma using Clotting Factor IX Deficient Plasma reagent.
Assay of protein C was done by activating it in the test plasma with a specific snake venom protein C activator reagent, thus inhibiting factors V and VIII in the added Protein C Deficient Plasma reagent and prolonging the subsequent PT171 test. The prolongation of PTT is a measure of the protein C concentration in the patient's plasma.
The study protocol conformed with the ethical guidelines of the 1975 Declaration of Helsinki as reflected. Informed consent was obtained from each patient. 
